Earnings Summary: Entrada Therapeutics Q4
Entrada Therapeutics Inc TRDA | 13.53 | -2.52% |
The earnings results for Entrada Therapeutics (NASDAQ:TRDA) for Q4 were made public on Thursday, February 26, 2026 at 07:00 AM.
Here's a comprehensive overview of the announcement.
Earnings
Entrada Therapeutics beat estimated earnings by 22.95%, reporting an EPS of $-0.94 versus an estimate of $-1.22.
Revenue was down $36.10 million from the same period last year.
Historical Earnings Summary
Last quarter the company missed on EPS by $0.07 which was followed by a 0.58% drop in the share price the next day.
Here's a look at Entrada Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.99 | -0.86 | -0.72 | -0.66 |
| EPS Actual | -1.06 | -1.04 | -0.42 | 0.03 |
| Revenue Estimate | 7.32M | 8.45M | 11.95M | 12.92M |
| Revenue Actual | 1.61M | 1.95M | 20.56M | 37.40M |
Listen to the earnings announcement yourself by clicking here.
To track all earnings releases for Entrada Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.